| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5616652 | The Journal of Thoracic and Cardiovascular Surgery | 2017 | 17 Pages |
Abstract
This study proves an intermediate improvement of ischemia/reperfusion-injured lung transplants by the CD26/DPP4-inhibitor vildagliptin up to 14 days. Enhanced levels of SDF-1 induced an anti-inflammatory effect on a cellular and protein level, and render CD26/DPP4 inhibition preconditioning effective for the protection from lung ischemia/reperfusion injury.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Jae-Hwi PhD, Yoshito MD, PhD, Florian MSc, Ingrid PhD, Lesley PhD, Gwendolyn MSc, Ilhan MD, Shampa PhD, Walter MD, Wolfgang MD, PhD,